Table 1.
Baseline characteristics of participants included and excluded in our subgroup.
| Characteristics | Included (N = 387) | Excluded (N = 288) | P value |
|---|---|---|---|
| Age, y, median (IQR) | 61 (55–67) | 61 (54–67) | 0.85 |
| Female, n (%) | 110 (28.4) | 71 (24.7) | 0.27 |
| BMI, kg/m2, median (IQR) | 24.5 (22.6–26.8) | 24.9 (22.9–27.3) | 0.19 |
| Medical history, n (%) | |||
| Hypertension | 238 (61.5) | 173 (60.1) | 0.71 |
| Dyslipidaemia | 29 (7.5) | 12 (4.2) | 0.07 |
| Diabetes mellitus | 96 (24.8) | 68 (23.6) | 0.72 |
| Ischemic stroke | 73 (18.9) | 48 (16.7) | 0.46 |
| TIA | 11 (2.8) | 7 (2.4) | 0.74 |
| Coronary artery disease | 16 (4.1) | 35 (12.2) | <0.0001 |
| Current smoker | 171 (44.2) | 148 (51.4) | 0.08 |
| Drug use before randomization, n (%) | |||
| Proton-pump inhibitor | 4 (1.0) | 1 (0.4) | 0.30 |
| Statin | 49 (12.7) | 17 (5.9) | 0.004 |
| Aspirin | 97 (25.1) | 49 (17.0) | 0.01 |
| Clopidogrel | 10 (2.6) | 5 (1.7) | 0.46 |
| Ticagrelor | 0 (0.0) | 0 (0.0) | - |
| Time from onset to randomization, h, median (IQR) | 15.4 (8.5–20.8) | 12.9 (7.7–20.6) | 0.07 |
| Qualifying event, n (%) | 0.89 | ||
| Minor stroke | 324 (83.7) | 240 (83.3) | |
| TIA | 63 (16.3) | 48 (16.7) | |
| NIHSS, median (IQR); mean ± SD | 2(1–3); 1.60 ± 1.13 | 2(1–3); 1.63 ± 1.10 | 0.049 |
| Baseline ABCD2 score, median (IQR) | 5 (4,5) | 5 (4,5) | 0.91 |
| SSS-TOAST stroke subtype, n (%) | 0.44 | ||
| Large-artery atherosclerosis | 181 (55.9) | 123 (51.3) | |
| Cardioaortic embolism | 7 (2.2) | 6 (2.5) | |
| Small-artery occlusion | 113 (34.9) | 100 (41.7) | |
| Other causes | 11 (3.4) | 5 (2.1) | |
| Undetermined causes | 12 (3.7) | 6 (2.5) |
IQR, interquartile range; SD, standard deviation; BMI, body mass index; TIA, transient ischaemic attack; ABCD2, age, blood pressure, clinical features, duration of TIA, and presence of diabetes score squared; SSS-TOAST, Stop Stroke Study-Trial of Org 10172 in Acute Stroke Treatment.